Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by stanleyon Jul 26, 2012 12:03pm

144 Views

Post# 20154937

RE: Manipulation

Terry:

Excellent link. I've always cautioned the "newbies" that T1's, T2's and T3's facing expropriation (etc) overseas could be be using their significant cash position (leverage) to box in target (junior) companies. They then make offers that management cannot refuse.

BWDIK? Are the regulators busy regulating? What do we get for our listing fees? Options, rights & warrants issued and outstanding.

Cheers

Stanley

Bullboard Posts

Rick Rule’s election insights: Gold, USD, and Canadian gas